BioWink, the Germany-based women’s health app developer backed by pharmaceutical firm Dr Kade, closed a $7m series A round co-led by venture capital firms Union Square Ventures and Mosaic Ventures on Friday.
Founded in 2013, BioWink has developed an app called Clue that tracks and predicts a woman’s menstrual cycle by analysing data points such as mood, body temperature and sexual activity. The app provides an insight into when the user has an increased chance of conceiving a child.
BioWink claims Clue has more than two million active users across the world. The cash will go towards the development of new features, recruitment and international expansion, and BioWink also hopes to ink agreements with universities to conduct research into reproductive health.
The company has now raised a total of approximately $10m. Groupe Arnault, the holding company for luxury goods producer LVMH, and Dr Kade took part in a $2m seed round alongside a range of angel investors in March this year.
BioWink had already secured a total of €1m ($1.1m) across two seed rounds in February and August 2014 from Luminary Labs Ventures and several private investors.